MiNK Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INKT research report →
Companyminktherapeutics.com
MiNK Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
- CEO
- Jennifer S. Buell
- IPO
- 2021
- Employees
- 23
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $53.41M
- P/E
- -4.12
- P/S
- 0.00
- P/B
- -4.05
- EV/EBITDA
- -3.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 76.02%
- ROIC
- -415.48%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-12,494,260 · -15.85%
- EPS
- $-2.93 · -1.03%
- Op Income
- $-12,487,304
- FCF YoY
- -61908.09%
Performance & Tape
- 52W High
- $76.00
- 52W Low
- $6.65
- 50D MA
- $11.03
- 200D MA
- $12.46
- Beta
- 0.47
- Avg Volume
- 312.63K
Get TickerSpark's AI analysis on INKT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 23, 25 | Holcomb John Bradley | other | 4,174 |
| Mar 13, 26 | Orilall Melissa | other | 0 |
| Mar 13, 26 | Charette Austin | other | 0 |
| Mar 9, 26 | Ryan Barbara | sell | 200 |
| Mar 10, 26 | Ryan Barbara | sell | 300 |
| Mar 10, 26 | Ryan Barbara | sell | 500 |
| Mar 10, 26 | Ryan Barbara | sell | 500 |
| Feb 27, 26 | Ryan Barbara | sell | 400 |
| Mar 2, 26 | Ryan Barbara | sell | 100 |
| Jan 2, 26 | Buell Jennifer | other | 10,024 |
Our INKT Coverage
We haven't published any research on INKT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INKT Report →